There were no significant differences between the TNFi groups in terms of sex, age, HLA-B27 positivity, history of AU before TNFi initiation, other extra-articular manifestations (i.e., psoriasis and inflammatory bowel disease), or number of recurrences prior to TNFα inhibitor use (Table 2), indicating baseline comparability. This evidence concerns the gene TNF and inflammatory bowel disease.